Trial Profile
Identifying factors associated with a higher than expected residual Rivaroxaban plasma concentration in a large group of real-life patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 06 Apr 2018
Price :
$35
*
At a glance
- Drugs Rivaroxaban (Primary)
- Indications Embolism and thrombosis
- Focus Pharmacodynamics
- 06 Apr 2018 New trial record
- 03 Apr 2018 Results published in the Thrombosis and Haemostasis